On Monday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened higher 7.92% from the last session, before settling in for the closing price of $5.05. Price fluctuations for TSHA have ranged from $1.05 to $5.51 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -63.99% annually for the last half of the decade. Company’s average yearly earnings per share was noted -0.79% at the time writing. With a float of $223.27 million, this company’s outstanding shares have now reached $273.92 million.
In an organization with 73 employees, it is important to assess its efficiency.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 18.49%, while institutional ownership is 89.58%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,172,812. In this transaction President and Head of R&D of this company sold 260,047 shares at a rate of $4.51, taking the stock ownership to the 1,006,439 shares. Before that another transaction happened on Nov 28 ’25, when Company’s President and Head of R&D sold 110,125 for $4.75, making the entire transaction worth $523,094. This insider now owns 1,006,439 shares in total.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.07 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.08) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.45% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 10.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 236.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 3.71 million. That was inferior than the volume of 3.85 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 91.74%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 97.19%, which indicates a significant increase from 94.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.53, while its 200-day Moving Average is $2.90. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $5.63. Second resistance stands at $5.80. The third major resistance level sits at $6.07. If the price goes on to break the first support level at $5.19, it is likely to go to the next support level at $4.92. The third support level lies at $4.75 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 273,919K shares outstanding in the company with a market cap of 1.49 billion. Presently, the company’s annual sales total 8,330 K according to its annual income of -89,300 K. Last quarter, the company’s sales amounted to 1,990 K and its income totaled -26,880 K.
